Gilead, Novo Nordisk expand NASH clinical collaboration EP News Bureau Mar 18, 2021 Triple combination regimen to be investigated in new Phase 2b study in NASH patients with cirrhosis
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations EP News Bureau Mar 15, 2021 Collaboration to focus on oral and injectable formulations of Lenacapavir and Islatravir
Healthcare industry records 103 deals worth $55.3 billion in December 2020 EP News Bureau Jan 7, 2021 One big-ticket deal contributes 70.5 per cent of the total deal value in December 2020
Gilead, Galapagos amend commercialisation and development pact for Jyseleca (filgotinib) EP News Bureau Dec 16, 2020 Under the new arrangement, Galapagos will assume sole responsibility in Europe for filgotinib in RA, Gilead to receive royalties…
Gilead Sciences to acquire MYR GmbH EP News Bureau Dec 10, 2020 Gilead to acquire Hepcludex, a first-in-class entry inhibitor, for treatment of chronic hepatitis delta virus (HDV), after closing…
Gilead Sciences, AIDS Society of India survey highlights disruption in HIV care during COVID-19 EP News Bureau Nov 30, 2020 Main reasons for disruption in India include travel constraints, fear of getting COVID-19
Trodelvy from Immunomedics extends survival in breast cancer patients Reuters Sep 19, 2020 The FDA granted the drug accelerated approval for its use in metastatic triple-negative breast cancer (mTNBC) patients who had…
Saptagir Labs signs manufacturing deal with Jubilant Generics for remdesivir EP News Bureau Sep 14, 2020 The drug will be produced at its sterile drug product manufacturing plant in Hyderabad which is WHO GMP certified
Gilead may soon buy Immunomedics in deal over $20 billion Reuters Sep 13, 2020 The deal, which will expand Gilead’s oncology portfolio, might get announced tomorrow if not sooner, inform reports
Gilead and Jounce Therapeutics sign exclusive license pact for novel immunotherapy program EP News Bureau Sep 1, 2020 Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop…